低疾病活动度(不论基线血清学状态)与接受贝利尤单抗治疗的系统性红斑狼疮患者糖皮质激素剂量及 flare 次数减少相关:一项真实世界观察性研究
多中心前瞻性观察性研究纳入 91 例因活动性疾病且对至少一种传统免疫抑制剂难治而接受贝利尤单抗至少 3 个月的 SLE 患者。贝利尤单抗显著降低平均 SLEDAI-2K、PGA 和每日泼尼松剂量,9-12 个月时超过 40% 的完成者达到 LLDAS,且血清学活动与不活动两组间 LLDAS 达成无差异;前 12 个月 flare 次数减少 62%、严重 flare 减少 50%。
要点
- 贝利尤单抗治疗后平均 SLEDAI-2K、PGA 和每日泼尼松剂量随时间显著下降,最早在起始后 3 个月出现。
- 超过 40% 的完成者在 9-12 个月时达到 LLDAS,血清学活动与不活动两组间无差异。
- 前 12 个月 flare 次数减少 62%、严重 flare 减少 50%。
核心结论
- 在真实世界中,贝利尤单抗可使超过 40% 的未经选择患者达到低疾病活动度,并伴随糖皮质激素剂量和 flare 次数减少。
- 血清学活动与血清学不活动的患者均对贝利尤单抗有应答。
研究设计与样本
- 多中心前瞻性观察性研究,连续纳入因活动性疾病且对至少一种传统免疫抑制剂难治而接受贝利尤单抗至少 3 个月的 SLE 患者,共 91 例。
- 记录疾病活动度(包括 LLDAS 和缓解即临床 SLEDAI-2K=0)、器官损害累积、flare 和副作用。
主要发现
- 91 例患者中女性占 94.5%,平均(SD)年龄 45.9(12.5)岁;最常见表现为关节炎(76.7%)、皮疹(72.5%)、血清学活动(低 C3/C4 和/或高抗 dsDNA;54.9%)、脱发(47.2%)和黏膜溃疡(27.5%)。
- 治疗中位(范围)持续时间为 10.5(3.0-42.1)个月;贝利尤单抗显著降低平均 SLEDAI-2K、PGA 和每日泼尼松剂量,最早在起始后 3 个月出现,超过 20% 的患者停用糖皮质激素。
- 临床(即排除血清学)SLEDAI-2K 下降在基线血清学活动患者中更明显(12 个月时从 8 降至 1.5),而基线血清学不活动患者为从 6 降至 4;但两组 LLDAS 达成无差异,完成者中超过 40% 在 9-12 个月时达到 LLDAS。
- 治疗前 12 个月内 flare 次数和严重 flare 次数分别减少 62% 和 50%。
- 20 例(22.0%)因应答不足停药,2 例因可能与药物相关的副作用停药。
关键数值与推荐
- LLDAS 达成:完成者中超过 40% 在 9-12 个月时达到,血清学活动与不活动两组间无差异。
- flare 次数减少 62%,严重 flare 次数减少 50%(治疗前 12 个月内)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low disease activity is a validated target of current systemic lupus erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to achieve low disease activity states in real-life settings. METHODS: Multicentre prospective observational study of consecutive SLE patients receiving belimumab for at least 3 months, due to active disease refractory to at least one conventional immunosuppressant. Disease activity, including the recently defined lupus low disease activity state (LLDAS) and remission (clinical SLEDAI-2K = 0), accrual of organ damage, flares and side effects were documented. RESULTS: Ninety-one patients were included [94.5% women, mean (SD) age 45.9 (12.5) years]. Most frequent manifestations were arthritis (76.7%), rash (72.5%), serologic activity (low C3/C4 and/or high anti-dsDNA; 54.9%), hair loss (47.2%) and mucosal ulcers (27.5%). Median (range) duration of treatment was 10.5 (3.0-42.1) months. Belimumab significantly decreased average SLEDAI-2K, physician global assessment (PGA) and daily prednisone dose over time, as early as 3 months after initiation, with over 20% of patients discontinuing corticosteroids. Although reduction in clinical (i.e., excluding serology) SLEDAI-2K was more pronounced in patients who were serologically active (from 8 to 1.5 at 12 months) as compared to serologically inactive (from 6 to 4) at baseline, attainment of LLDAS did not differ between the two groups and was reached by more than 40% of completer patients after 9-12 months. In addition, the number of flares and severe flares was reduced by 62% and 50%, respectively, during the first 12 months of treatment. Twenty patients (22.0%) discontinued treatment due to inadequate response and two due to side effects potentially related to the drug. CONCLUSIONS: In real-life, belimumab is efficacious in achieving low disease activity in over 40% of unselected patients, in combination with reduction of corticosteroid dosage and number of flares. Both serologically active and inactive patients respond to the drug.
引用
- Fanouriakis A, Adamichou C, Koutsoviti S, et al. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. Semin Arthritis Rheum. 2018. PMID: 29555348. doi:10.1016/j.semarthrit.2018.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。